– , /PRNewswire/ -- and (together AusperBio), a clinical-stage biotechnology company, today announced the clinical data of the Company's HBV ASO molecule, AHB-137, will be presented in two late-breaking posters, and , at the annual European Association for the Study of the Liver (EASLTM) Congress 2024, to be held in , from . These posters will highlight new data from two Phase I clinical studies conducted both globally and in , evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of . Poster presentation details are as follows: Safety and antiviral activity of AHB-137, a novel antisense oligonucleotide, in healthy volunteers and subjects with chronic hepatitis B : Late breaker posters Available from Prof.
, University of A phase 1, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of AHB-137 in Chinese healthy volunteers and subjects with chronic hepatitis B Late breaker posters Available from Wen Wang, The First Hospital of University, The full scientific program for The International Liver Congress 2024, as well as the abstracts, can be found at . AHB-137, a novel unconjugated antisense oligonucleotide ( ) developed within AusperBio's proprietary technology platform, is emerging as a promising candidate in the quest for a functional cure for chronic hepatitis B. Its compelling preclinical data was highlighted at the 2023 EASLTM conference.
This novel dual-mechanism ASO is curr.
